"
Team:Washington/Project/Safety/Secretion
From 2010.igem.org
(Difference between revisions)
| Line 27: | Line 27: | ||
Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from ''Pseudomonas aeruginosa'' PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI?? | Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from ''Pseudomonas aeruginosa'' PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI?? | ||
| - | The toxin we work with, Tse2, | + | The toxin we work with, Tse2, targets only prokaryotic cells, thus posing no danger. |
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS----------------------------------------> | <!---------------------------------------PAGE CONTENT GOES ABOVE THIS----------------------------------------> | ||
Revision as of 21:37, 9 September 2010
Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from Pseudomonas aeruginosa PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI??
The toxin we work with, Tse2, targets only prokaryotic cells, thus posing no danger.
